Dr. Benjamin Lowentritt, MD, FACS, Director, Minimally Invasive Surgery and Robotics and Cancer Care Program at Chesapeake Urology and an investigator on the ERLEADA ® (apalutamide) real-world study discusses the findings that showed a more than 90 percent decline in prostate-specific antigen (PSA) at six months in a majority of patients with mCSPC, reinforcing the positive results found in the clinical trial setting. The patient-reported outcomes study demonstrated that rapid and deep PSA decline is associated with improved health-related quality of life in advanced prostate cancer. These data were presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium 2022.
Dr. Lowentritt M.D., F.A.C.S. Director, Minimally Invasive Surgery and Robotics and Cancer Care Program, Chesapeake Urology.
Dr. Lowentritt has a general urology practice with a focus on minimally invasive techniques to treat urological conditions. His expertise includes robotic, laparoscopic, and endoscopic management of renal, bladder, and prostate cancer, as well as minimally invasive options for benign prostatic hyperplasia (BPH), kidney stones, pelvic organ prolapse, and ureteropelvic junction obstruction.
Dr. Lowentritt has been at the forefront of robotic urology procedures and was the first surgeon in Maryland to perform robot assisted surgery for bladder cancer.
He has authored numerous articles and chapters on subjects including robotic surgery, erectile dysfunction, pediatric urology, female urology and the urological management of patients after renal transplantation.
Dr. Lowentritt has been selected as a “Super Doctor” by his peers in The Washington Post magazine and as a “Top Doctor” in Baltimore magazine numerous times. Dr. Lowentritt serves on the Board of Directors for the Baltimore City Medical Society and is President of the AUA, Mid-Atlantic Region.